News

Targeted Oncology8h
ASCO 2025 Briefing: Advances in Breast, Lung, and Obesity-Linked Cancers
Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...